Journal Report

Urologic Oncology: Seminars and Original Investigations

Download PDF
Journal Information
Journal Title
Urologic Oncology: Seminars and Original Investigations
Publisher
Elsevier Inc.
ISSN
1078-1439
E-ISSN
1873-2496
Database
SCOPUS
Domain
Health Sciences, Life Sciences, Physical Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Adoption and perceptions of utility of the RENAL nephrometry score among fellowship-trained urologic oncologists in North America
Keenan Moore, Matthew Driscoll, Paige Wallner et al.
2026-11
DOI: 10.1016/j.urolonc.2026.10.006
Diagnostic value of CEUS-VI-RADS for predicting muscle invasion in bladder cancer: Validation of the scoring system and introduction of tumor-bladder wall contact length as a supplementary quantitative metric
Wenhao Qu, Ju Zhu, Yahan Yang et al.
2026-11 Vol. 44 Issue 11 Pages 859-865
DOI: 10.1016/j.urolonc.2026.08.023
Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy
Todd M. Morgan, Ching-Yu Wang, Halit O. Yapici et al.
2026-11 Vol. 44 Issue 11 Pages 960-967
DOI: 10.1016/j.urolonc.2026.08.016
Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China
Yujie Dong, Zhen Tian, Weilin Chen et al.
2026-11 Vol. 44 Issue 11 Pages 921-930
DOI: 10.1016/j.urolonc.2026.08.025
Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer
Lea Mantz, Alex Zhu, Nathaniel D Mercaldo et al.
2026-11 Vol. 44 Issue 11 Pages 946-959
DOI: 10.1016/j.urolonc.2026.08.013
Risk of androgen deprivation therapy after active surveillance for prostate cancer: A real-world analysis
James R. Janopaul-Naylor, Dattatraya Patil, Nikhil T. Sebastian et al.
2026-11 Vol. 44 Issue 11 Pages 866-872
DOI: 10.1016/j.urolonc.2026.08.014
Adherence to active surveillance monitoring among Medicare beneficiaries with prostate cancer
Jiaye Shen, Aaron J. Katz, Yahui Xie et al.
2026-11
DOI: 10.1016/j.urolonc.2026.10.008
Retraction notice to “Combination Chemotherapy with Docetaxel, Estramustine and Suramin for Hormone Refractory Prostate Cancer” [Urologic Oncology: Seminars and Original Investigations 23 (2005) 93–101]
Mohammad Reza Safarinejad
2026-11
DOI: 10.1016/j.urolonc.2026.10.002
Molecular profiling of renal mass biopsy tissue: A review of feasibility and clinical utility
Joseph McGrath, Robert Willis, Akash Sridhar et al.
2026-11
DOI: 10.1016/j.urolonc.2026.10.007
The AURKA–PTTG1 signaling axis induces enzalutamide resistance in prostate cancer
Guangye Han, Zhenhui Li, Weihang Song et al.
2026-11 Vol. 44 Issue 11 Pages 897-910
DOI: 10.1016/j.urolonc.2026.08.010
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 10, 2026 02:12